Synonym
CR-2945; CR2945; CR 2945
IUPAC/Chemical Name
(R)-5-((2,4-dimethyl-6-(8-azaspiro[4.5]decane-8-carbonyl)phenyl)amino)-3-(naphthalen-1-yl)-5-oxopentanoic acid
InChi Key
MFOOVZCXWVAWOV-RUZDIDTESA-N
InChi Code
InChI=1S/C33H38N2O4/c1-22-18-23(2)31(28(19-22)32(39)35-16-14-33(15-17-35)12-5-6-13-33)34-29(36)20-25(21-30(37)38)27-11-7-9-24-8-3-4-10-26(24)27/h3-4,7-11,18-19,25H,5-6,12-17,20-21H2,1-2H3,(H,34,36)(H,37,38)/t25-/m1/s1
SMILES Code
O=C(O)C[C@H](C1=C2C=CC=CC2=CC=C1)CC(NC3=C(C)C=C(C)C=C3C(N(CC4)CCC54CCCC5)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
526.68
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ekström J, Cevik Aras H. Parasympathetic non-adrenergic, non-cholinergic transmission in rat parotid glands: effects of cholecystokinin-A and -B receptor antagonists on the secretory response. Regul Pept. 2008 Feb 7;146(1-3):278-84. Epub 2007 Oct 22. PubMed PMID: 18006087.
2: Danzer M, Jocic M, Samberger C, Painsipp E, Bock E, Pabst MA, Crailsheim K, Schicho R, Lippe IT, Holzer P. Stomach-brain communication by vagal afferents in response to luminal acid backdiffusion, gastrin, and gastric acid secretion. Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286(3):G403-11. Epub 2003 Oct 30. PubMed PMID: 14592947.
3: Cevik Aras H, Ekström J. Pentagastrin-induced protein synthesis in the parotid gland of the anaesthetized rat, and its dependence on CCK-A and -B receptors and nitric oxide generation. Exp Physiol. 2006 Jul;91(4):673-9. Epub 2006 Mar 23. PubMed PMID: 16556659.
4: Aras HC, Ekström J. Cholecystokinin- and gastrin-induced protein and amylase secretion from the parotid gland of the anaesthetized rat. Regul Pept. 2006 May 15;134(2-3):89-96. Epub 2006 Mar 2. PubMed PMID: 16515811.
5: Lehmann F, Hildebrand P, Beglinger C. New molecular targets for treatment of peptic ulcer disease. Drugs. 2003;63(17):1785-97. Review. PubMed PMID: 12921485.
